CTNM

Contineum Therapeutics
$13.86
−$0.20 (−1.42%)Jul 27, 2026
3.6FairMoatMint rating

MoatMint rates Contineum Therapeutics (CTNM) 3.6 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 0.7 out of 10.

Key metrics

The numbers that frame CTNM today
Market cap
$518.18M
P/E (TTM)
-8.9
EV / FCF
-8.8
ROIC
-31.2%
Div yield
0%
Debt / equity
0.0
52wk Low
$5.07
52wk High
$16.91

CTNM stock rating

How CTNM scores on quality, value, growth, momentum and financial health
3.6out of 10
Fair overallFair business, expensive priceTop 64% of ~5,000 US stocks
QualityPoor0.7/10
GrowthNeutral5.3/10
MomentumGreat8.7/10
ValueFair2.2/10
Financial HealthNeutral5.8/10

Growth

Revenue and earnings trend for CTNM
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about CTNM
Is Contineum Therapeutics a good buy?
Hold. Contineum Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks mixed. The support signal is useful, but not decisive. We think Contineum Therapeutics is selling at a very high price.
What is the market capitalization of CTNM?
Contineum Therapeutics's market capitalization is $518.18M.
What is the P/E ratio for CTNM stock?
Contineum Therapeutics's current P/E ratio is -8.9.
What is the 52-week high for CTNM stock?
The 52-week high for Contineum Therapeutics is $16.91. The current close of $13.86 is 18% below that high.
What is the 52-week low for CTNM stock?
The 52-week low for Contineum Therapeutics is $5.07. The current close of $13.86 is 173.4% above that low.
Does CTNM stock pay dividends?
Contineum Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for CTNM?
Contineum Therapeutics's Debt / Equity ratio is 0.03.